mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-15. Anything still debated is marked as such rather than presented as settled.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Moreover, chloral hydrate is used as a reagent for the deprotection of acetals, dithioacetals and tetrahydropyranyl ethers in organic solvents. The compound can be crystallized in a variety of polymorphs.
Alsos Digital Library – Radioactive Waste (annotated bibliography) Euridice European Interest Group in charge of Hades URL operation (link) Ondraf/Niras, the waste management authority in Belgium (link) Critical Hour: Three Mile Island, The Nuclear Legacy, And National Security (PDF) Environmental Protection Agency – Yucca Mountain[link removed] (documents) Grist.org – How to tell future generations about nuclear waste (article) International Atomic Energy Agency – Internet Directory of Nuclear Resources (links) Nuclear Files.org – Yucca Mountain (documents) Nuclear Regulatory Commission – Radioactive Waste (documents) Nuclear Regulatory Commission – Spent Fuel Heat Generation Calculation (guide) Radwaste Solutions (magazine) UNEP Earthwatch – Radioactive Waste Archived 2008-12-23 at the Wayback Machine (documents and links) World Nuclear Association – Radioactive Waste Archived 2010-06-11 at the Wayback Machine (briefing papers) Worries can't be buried as nuclear waste piles up, Los Angeles Times, January 21, 2008
== Structure == LRP5 is a transmembrane low-density lipoprotein receptor that shares a similar structure with LRP6. In each protein, about 85% of its 1600-amino-acid length is extracellular. Each has four β-propeller motifs at the amino terminal end that alternate with four epidermal growth factor (EGF)-like repeats. Most extracellular ligands bind to LRP5 and LRP6 at the β-propellers. Each protein has a single-pass, 22-amino-acid segment that crosses the cell membrane and a 207-amino-acid segment that is internal to the cell.
Powstanie Wielkopolskie, [in:] J.Pajewski, Odbudowa państwa polskiego 1914–1918, Warszawa 1985, Janusz Pajewski, Znaczenia Powstania Wielkopolskiego dla odbudowy Państwa Polskiego w 1918 r., Zeszyty Naukowe UAM, Historia 1970, t.10 S. Rybka, Zerwane pęta. Wspomnienia z dni rewolucji niemieckiej i powstania polskiego 1918-1919, Poznań 1919 A. Rzepecki, Powstanie grudniowe w Wielkopolsce. 27 XII 1918, Poznań 1919 Z. Wieliczka, Wielkopolska w Prusy w dobie powstania 1918/1919, Poznań 1932 Z. Wroniak, Paderewski w Poznaniu, Kronika Miasta Poznania 1959, nr 4 H. Zieliński, Rola powstania wielkopolskiego oraz powstań śląskich w walce o zjednoczenie ziem zachodnich z Polską; (1918–1921), [in:] Droga przez Półwiecze. Dietrich Vogt: Der großpolnische Aufstand 1918/1919: Bericht, Erinnerungen, Dokumente. Marburg 1980 (J.-G.-Herder-Institut) ISBN 3-87969-147-9 Richard Blanke, Orphans of Versailles. The Germans in Western Poland 1918–1939, Lexington, KY., 1993 (presents somehow pro-German vision of the events)
== Antiquity == The first attempts at general anesthesia were probably herbal remedies administered in prehistory. Alcohol is the oldest known sedative; it was used in ancient Mesopotamia thousands of years ago.
Sources: en.wikipedia.org
=== Works cited === Adams, John, ed. (1805). The Annual Register, Or, A View of the History, Politics, and Literature for the Year ... J. Dodsley. Andrew, Christopher (2018). Secret World: A History of Intelligence. Yale University Press. ISBN 978-0-300-24052-8. Arnold, James R. (1995). Napoleon Conquers Austria: The 1809 Campaign for Vienna. Greenwood Publishing Group. ISBN 978-0-275-94694-4. Bell, David Avrom (2007). The First Total War: Napoleon's Europe and the Birth of Warfare as We Know it. Houghton Mifflin Harcourt. ISBN 978-0-618-34965-4. Black, Jeremy (2009). The War of 1812 in the Age of Napoleon. University of Oklahoma Press. ISBN 978-0-8061-4078-0. Briggs, Asa (1959). The Making of Modern England, 1783–1867: The Age of Improvement. Harper & Row. Bryant, Arthur (1944). Years of Victory, 1802–1812. Collins. Burke, Edmund (1808). The Annual Register, Or, A View of the History, Politics, and Literature for the Year ... J. Dodsley. Canales, Esteban (2004), 1808–1814: demografía y guerra en España (PDF) (in Spanish), Autonomous University of Barcelona, retrieved 3 May 2017 Chandler, David G. (1966). The Campaigns of Napoleon. Scribner. ISBN 978-0-02-523660-8. Clodfelter, Micheal (2017). Warfare and Armed Conflicts: A Statistical Encyclopedia of Casualty and Other Figures, 1492–2015 (4th ed.). McFarland. ISBN 978-1-4766-2585-0. Desan, Suzanne; Hunt, Lynn; Nelson, William Max (2013). The French Revolution in Global Perspective. Cornell University Press. ISBN 978-0-8014-6747-9. Dwyer, Philip (2013). Citizen Emperor: Napoleon in Power. Esdaile, Charles (2009).
=== Oxidative half === In the oxidative half of the mechanism, Cys63 nucleophilically attacks the nearest sulfide unit in the GSSG molecule (promoted by His467), which creates a mixed disulfide bond (GS-Cys58) and a GS− anion. His467 of GSR then protonates the GS- anion to release the first molecule of GSH. Next, Cys63 nucleophilically attacks the sulfide of Cys58, releasing a GS− anion, which, in turn, picks up a solvent proton and is released from the enzyme, thereby creating the second GSH. So, for every GSSG and NADPH, two reduced GSH molecules are gained, which can again act as antioxidants scavenging reactive oxygen species in the cell.
ATC code G04 Urologicals is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup G04 is part of the anatomical group G Genito-urinary system and sex hormones. Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QG04. ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.National versions of the ATC classification may include additional codes not present in this list, which follows the WHO version.
== Potential drug interactions == CoQ10 taken as a pharmacological substance has potential to inhibit the effects of theophylline as well as the anticoagulant warfarin; CoQ10 may interfere with warfarin's actions by interacting with cytochrome p450 enzymes thereby reducing the INR, a measure of blood clotting. The structure of CoQ10 is similar to that of vitamin K, which competes with and counteracts warfarin's anticoagulation effects. CoQ10 is not recommended in people taking warfarin due to the increased risk of clotting.
Sources: en.wikipedia.org
The case against the company was upheld in the United States Court of Appeals for the Ninth Circuit, and the Supreme Court of the United States declined to hear Chipotle's appeal, leaving the Ninth Circuit's ruling intact. Chipotle has "an official disability policy of bringing ingredients to the tables of diners with disabilities and doing tableside preparation." Chipotle is retrofitting restaurants affected by the ruling, replacing the walls in front of the food preparation area with lower ones or transparent panels. They are incorporating the new design elements into new restaurants. The case was one of over twenty ADA-related lawsuits filed by Antoninetti, who died in 2011.
Dipipanone, sold under the brand names of Pipadone and Diconal is a strong opioid analgesic drug, used for acute pain by mouth (PO) for adults. It is often used in instances where morphine is indicated but cannot be used due to the patient being allergic to morphine. In analgesic potency 25 mg dipipanone is approximately equivalent to 10 mg morphine.
Cervical drug delivery serves as a route for compounds to prevent and treat sexually transmitted diseases (STDs). Prevention of STDs for women can be achieved by administering preventative compounds into the vaginal canal prior to intercourse. One method researched is the use of a CAP technology that remains stable in the vaginal environment, but breaks down in the presence of human semen, releasing a drug to destroy STDs. This application of cervical drug delivery would be useful for prevention of STDs in women without interfering with the bodily environment until there is potential for infection. STDs can also be treated through cervical drug delivery methods. Antibiotics for STD treatment are often administered into the vagina in the form of creams or gels.
2 NpO2 + H2 + 6 HF → 2 NpF3 + 4 H2O (400°C) 2 NpF3 + O2 + 2 HF → 2 NpF4 + H2O (400°C) Later, NpF4 was obtained directly by heating NpO2 to various temperatures in mixtures of either hydrogen fluoride or pure fluorine gas. NpF5 is much more difficult to form and most known preparation methods involve reacting NpF4 or NpF6 compounds with various other fluoride compounds. NpF5 will decompose into NpF4 and NpF6 when heated to around 320 °C. NpF6 or neptunium hexafluoride is extremely volatile, as are its adjacent actinide compounds uranium hexafluoride (UF6) and plutonium hexafluoride (PuF6). This volatility has attracted a large amount of interest to the compound in an attempt to devise a simple method for extracting neptunium from spent nuclear power station fuel rods. NpF6 was first prepared in 1943 by reacting NpF3 and gaseous fluorine at very high temperatures and the first bulk quantities were obtained in 1958 by heating NpF4 and dripping pure fluorine on it in a specially prepared apparatus. Additional methods that have successfully produced neptunium hexafluoride include reacting BrF3 and BrF5 with NpF4 and by reacting several different neptunium oxide and fluoride compounds with anhydrous hydrogen fluorides. Four neptunium oxyfluoride compounds, NpO2F, NpOF3, NpO2F2, and NpOF4, have been reported, although none of them have been extensively studied. NpO2F2 is a pinkish solid and can be prepared by reacting NpO3·H2O and Np2F5 with pure fluorine at around 330 °C.
When Eng arrived at Amylin's San Diego headquarters, he was astonished to discover how much information Amylin's scientists had already figured out about exendin-4 in the brief period of time after Young saw his poster, which convinced him that Amylin was the right company to partner with. Amylin went on to create exenatide, a synthetic version of exendin-4, and later formed an alliance with Lilly in 2002 to bring the drug to market. Exenatide was predicted by Amylin scientist Alain Baron to begin undergoing the Food and Drug Administration's approval process in 2004. Exenatide was approved by the FDA in April 2005, for people whose diabetes is not well controlled on other oral medications. This was a landmark event which proved that targeting the GLP-1 receptor was a viable strategy and inspired other pharmaceutical companies to focus their research and development on that receptor. In 2011, Lilly and Amylin dissolved their partnership, with Amylin keeping the rights to exenatide. Meanwhile, Lilly had been awakened to the possibilities of this class of drugs and continued to develop newer drugs of the same class. By October 2024, the blockbuster drug tirzepatide had transformed Lilly into the most valuable drug company in the world.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Reversed-phase liquid chromatography with ultraviolet detection is the standard approach, reported as area percent of the main peak. Orthogonal methods such as mass spectrometry confirm that the main peak has the expected mass. Purity figures are only comparable when column, gradient, and wavelength are matched.